NCT03093428View on ClinicalTrials.gov

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

April 9, 2020

Study Completion Date

February 28, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Radium-223

Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.

DRUG

Pembrolizumab

Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03093428 - Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | Biotech Hunter | Biotech Hunter